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Background
Melanoma is an immunogenic cancer that overcomes the
immune surveillance through the production of tolerogenic
cytokines and growth factors within microenvironment.
Melanoma-derived dendritic cells (DCs) show altered
maturation, cross-priming and antigenic presentation and
their major defect concerns the activation of the STAT
pathway. The prognostic criteria to define melanoma at
high-risk of relapse/recurrence include the Breslow depth,
the Clark level and number of mitosis. Sentinel lymph
node (SLN) characterization is a prognostic factor in mela-
noma, although false negative occurs in approximately 5%
of patients. We investigated the potential prognostic role of
DC number variation in relation to clinical stage, and sug-
gest their role as early predictor of high risk melanomas.
Methods
84 patients (group A; stage I-IV) with a previously definite
diagnosis of melanoma as well as 18 (group B) with highly
suspected cutaneous lesion were enrolled into the study.
Peripheral blood was collected at study entry in patients of
group A, whereas cells from group B were collected before
and after the primary tumor exeresis and then before/after
any surgical procedure including SLN, lymphadenectomy
or metastasis removal. Both myeloid (m) and plasmacytoid
(p) DCs were investigated by flow-cytometry using the anti-
Lin, -CD11c, -BDCA-1, -CD123, and -BDCA-2 MoAbs.
The percentage number of both mDCs and pDCs was cor-
related to clinical stage as well as to indipendent prognostic
factors as histological features including Breslow, Clark
level, presence/absence of tumor-infiltrating lymphocytes,
and BRAF V600E/K mutations.
Results
The percentage of both mDCs and pDCs from group A
were similar in stage I-III and dramatically reduced in
those at stage IV. A. Lack of correlation was also demon-
strated with clinical features and prognostic factors. By
contrast, data from group B showed: an increase of mDCs
and pDCs (p<0.05) after tumor removal as well as in those
with negative SLN whereas both subsets resulted
unchanged in patients with positive SLN. A weak trend to
DC increase occurred in patients undergoing negative
lymphoadenectomy. Number of mDCs and pDCs from
group B was correlated with histological features and
unrelated to mutational status.
Conclusions
These findings suggest the critical pathogenetic role of DC
in melanoma and their measurement may be thus pro-
posed as additional prognostic factor to limit the risk of
underscoring the melanoma stage of patients at high risk
of relapse/recurrence.
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